Factor TX is a vitamin K-dependent blood dotting zymogen that is functionally defective or absent in patients with hemophilia B. A method of imnmunoaffinity chromatogiaphy has been developed for a one-step high yield purification of factor IX directly front plasma. The technique utilizes conformation-specific antibodies that bind solely to the metal-stabilized factor TX conformer, but not to the conformer of factor IX found in the absence of metal ions. Anti-factor IXCa(II) antibodies were immobilized on an agarose matrix. Human plasma in the presence of 7.5 mM MgCI2 was applied to the antibody-agarose column. The factor TX that binds to these antibodies was specifically eluted by metal chelation with EDTA. This immunopurification resulted in a 10,000-fold onestep purification of the fully functional zymogen. Purified factor TX yielded a single band upon gel electrophoresis in NaDodSO4 and had a specific activity of 120-150 units/mg. The purified factor IX was separated from other vitamin K-dependent blood clotting proteins and hepatitis virus; no activated factor TX was detected. This method has application for the large scale purification of factor TX for the treatment of hemophilia B.
Factor IX, a vitamin K-dependent plasma protein with a molecular weight of 56,000, plays a central role in blood coagulation (1, 2) . This protein is deficient or functionally defective in patients with hemophilia B (3) (4) (5) . The vitamin K-dependent blood coagulation proteins, including factor IX, constitute a class of calcium-binding proteins that contain 'Y carboxyglutamic acid residues, which confer their metalbinding properties (6, 7) . Their interaction with metal ions results in a change in the tertiary structure of these proteins, which is essential for their function. This conformational transition has been demonstrated for prothrombin by circular dichroism (8) , fluorescence quenching (9) , and immunochemical methods using conformation-specific rabbit polyclonal (10) and murine monoclonal antibodies (11) that bind solely to the metal-stabilized conformation.
Although we have used these conformation-specific antibodies to develop specific immunoassays for prothrombin species with various contents of y-carboxyglutamic acid (12, 13) , we have recently recognized the advantages of conformation-specific antibodies for the immunoaffinity chromatographic purification of proteins. Unlike standard methods for immunopurification, in which the harsh conditions required for the dissociation of the antibody-antigen complex can lead to denaturation and loss of function of the protein (14) , this method involves mild and specific elution conditions. Antibodies that only recognize the metal-stabilized conformer of the protein are used to transiently immobilize the protein to a solid support. The antibody-protein complex is disrupted by the removal of bound metal ions from the protein with a metal chelator. The general technique, applied to the purification of factor IX (Christmas factor), has potential application for the large scale purification of factor IX for specific replacement therapy in hemophilia B.
EXPERIMENTAL PROCEDURES Purification of Human Factor IX, Prothrombin, and Factor X. Prothrombin, factor X, and factor IX were isolated from fresh frozen human plasma by sequential barium citrate adsorption and elution, DEAE-Sephadex chromatography, DEAE-cellulose chromatography, and heparin-Sepharose chromatography (15, 16) . Human factor X was further purified on an anti-prothrombin-Sepharose column. The purified proteins each migrated as a single band upon electrophoresis in NaDodSO4/polyacrylamide gels (17) . In the presence of 2-mercaptoethanol, factor X was completely reduced; its heavy and light chains migrated separately upon NaDod-S04/PAGE. Prothrombin activity was determined by using a one-stage prothrombin assay (18) . Factor X activity was determined by a modified Russell's viper venom coagulant assay using factor X-deficient plasma (19) . Factor IX activity was determined with a two-stage assay using factor IX-deficient plasma (20) .
Protein concentrations of complex biological fluids were estimated by a Coomassie protein-binding assay using bovine serum albumin as a standard (21) . The protein concentrations of purified coagulation proteins were estimated by using the following extinction coefficients: factor IX, Al% 13.3; factor X, A2j0 11.6; prothrombin, A28 14.4.
Purified factor IX was coupled to cyanogen bromide-activated Sepharose-4B at a concentration of 4.3 mg per ml of Sepharose (total vol, 4 ml of Sepharose) (22) .
Preparation of Anti-Factor TX-Ca(TT) Antibodies. New Zealand White rabbits were immunized with factor IX. Antibodies specific for the metal-stabilized conformation of factor IX [anti-factor IX-Ca(II)] were purified by affinity chromatography on the human factor IX-Sepharose column (1.5 x 3 cm) as a modification of the technique of Tai et al. (10) . Antiserum was dialyzed overnight in 0.05 M Tris HCl, pH 7.4/0.14 M NaCl/3 mM CaCl2/0.05% NaN3 (buffer A/CaCl2). The factor IX-Sepharose column was equilibrated with the same buffer and the antiserum was applied to the column. The column was exhaustively washed with the buffer A/CaCl2 to remove unbound protein. In certain experiments that evaluated the role of metal ions in antibody-antigen interaction, reagents were rendered metal-free by exhaustive dialysis against metal-free water or passage over a Chelex 100 column. Metal-free water, prepared using Chelex 100, was used to wash glassware and to prepare all buffers.
Competition ELISA for Factor IX-Anti-Factor IX Binding. The antigenic specificity of rabbit anti-factor IX-Ca(II) antibody was studied by using a competition ELISA system. Anti-factor IX-Ca(II) antibody (5 x 10-8 M) was added to various concentrations of competitor (prothrombin, factor IX, or factor X), incubated for 30 min at 37°C, and then 50 A was added to the microtiter wells. The interaction between competitor and antibody was assessed by the inhibition of antibody binding to the factor IX bound to the solid phase.
Radioimmunoassay of Native Factor IX. Fully carboxylated (native) factor IX was measured by radioimmunoassay using anti-factor IX-Ca(II) antibody and 125I-labeled factor IX. Factor IX was iodinated using Na125I (New England Nuclear) with the chloramine-T method (23) . The assay is analogous to that previously reported for native prothrombin (12, 13) . Normal human plasma was derived from a pool of plasma donations. Plasma from a patient with hemophilia B had <1% factor IX coagulant activity and <1% factor IX antigen, as determined by radioimmunoassay.
Isolation of Factor IX by Using Anti-Factor IX-Ca(I) Antibody Atfinity Columns. A factor IX-enriched material was prepared by absorption of plasma (200 ml) to barium citrate, followed by elution of the vitamin K-dependent coagulation proteins (15, 16 7 .4/0.5 M NaCl/0.02% Tween 20/0.05% NaN3, and then brought to 7.5 mM MgCl2 prior to application to the column. After the column was washed exhaustively with equilibration buffer, the bound factor IX was eluted with the 10 mM EDTA buffer.
Materials. DEAE-Sephadex and Sepharose-4B were obtained from Pharmacia, DEAE cellulose was from Whatman, and Chelex 100 was from Bio-Rad. Bovine serum albumin (RIA grade), goat anti-rabbit antibody conjugated to alkaline phosphatase, p-nitrophenylphosphate, plasmas deficient in factors II-VII and factors X-VII were obtained from Sigma. The AUSRIA II radioimmunoassay for hepatitis B surface antigen was obtained from Abbott. All chemicals used were reagent grade.
RESULTS
Preparation of Anti-Factor IX-Ca(II) Antibodies. Rabbit antiserum was applied to the factor IX-Sepharose column in the presence of 3 mM CaCl2. After removal of unbound protein, the anti-factor IX-Ca(II) antibodies were eluted with 5 mM EDTA (Fig. 1) . The remaining factor IX antibodies were eluted with 4 M guanidine HCl. The anti-factor IX-Ca(II) antibodies represented =20% of the anti-factor IX antibodies in the antiserum.
Characterization of Anti-Factor IX-Ca(II) Antibodies. The effect of metal ions on the interaction of anti-factor IXCa(II) antibodies with factor IX was studied. Anti-factor IXCa(II) bound to factor IX in the presence of 3 mM CaCl2, but not in the presence of 5 mM EDTA (Fig. 2) . Other metal ions could also support the binding of anti-factor IX-Ca(II) antibodies to factor IX (Fig. 3 The specificity of the anti-factor IX-Ca(II) antibody was studied using a competition ELISA (Fig. 4A) . Under the conditions used, anti-factor IX-Ca(II) antibodies do not bind to either factor X or prothrombin. Since the six known vitamin K-dependent blood clotting proteins are structurally homologous, we further evaluated the interaction of anti-factor IX-Ca(II) antibody with factor IX and these other proteins. As shown in Fig. 4B , the interaction of anti-factor IX-Ca(II) antibody and 1251-labeled factor IX is inhibited by normal plasma. However, plasma from a patient with hemophilia B, lacking factor IX antigen, did not significantly inhibit antibody-'251-labeled factor IX binding. Since the levels of factor VII, protein C, protein S, factor X, and prothrombin are normal in hemophilia B, these results indicate that this antibody population is specific for factor IX.
Immunoaffinity Purification of Factor IX. A barium citrate eluate derived from plasma, enriched in the vitamin K-dependent blood coagulation proteins, was applied to the antifactor IX-Ca(II)-Sepharose column. The factor IX bound to the column in the presence of 7.5 mM MgCl2 and was eluted with 10 mM EDTA. The eluted factor IX had a specific activity of 151 units per mg of protein and contained no detectable prothrombin or factor X activity (Table 1) . A 250-fold purification over the barium citrate eluate was realized, with a recovery of 77% of the factor IX activity applied to the column. The eluted factor IX migrated as a single band upon electrophoresis in the presence of NaDodSO4 (Fig. 5) in a single step by the immunoaffinity procedure. Human plasma, after dialysis, was applied to the affinity column in the presence of 7.5 mM MgCl2. All detectable factor IX activity was removed from the plasma by the immunoabsorbent. Factor IX, eluted with 10 mM EDTA, had a specific activity of 124 units per mg of protein (Table 1 ). This represents a 10,000-fold purification with an 81% recovery of the plasma factor IX activity. The eluted factor IX migrated on NaDodSO4/PAGE as a single band (Fig. 6) .
The anti-factor IX-Ca(II)-Sepharose column was repeatedly used for the isolation of factor IX from plasma. The specific activity of the purified factor IX from these preparations ranged between 118 and 138 units per mg. The final recovery of factor IX for these preparations varied between 68% and 84% of the factor IX activity in the starting plasma.
Separation of Factor TX from Hepatitis B Virus. Partially purified factor IX concentrates used in the treatment of hemophilia B are associated with a high risk of hepatitis virus contamination. We questioned whether the purified factor IX prepared by immunoaffinity chromatography would be free of viral contaminants. Ascites (1 ml) from a patient with primary hepatocellular carcinoma, rich in hepatitis B virus as measured by the assay of hepatitis B surface antigen, was added to fresh frozen plasma (200 ml). The factor IX was purified by immunoaffinity chromatography, as described above, using anti-factor IX-Ca(II)-Sepharose. Viral surface antigen was measured by radioimmunoassay in column fractions. Within the limits of detection, all of the hepatitis B surface antigen failed to bind to the affinity matrix. There was no detectable hepatitis virus in the EDTA eluate containing factor IX (Fig. 7) . After a 50-fold concentration of the factor IX fractions, no hepatitis virus was detectable. Within the limits of detection these results indicate that factor IX is separated from hepatitis virus during its purification.
DISCUSSION
Factor IX is a trace protein in blood that has a central role in blood coagulation (1, 2) . Patients with hemophilia B, in whom this protein is deficient or functionally defective, have a significant bleeding tendency. The severe bleeding disorder in these patients emphasizes the importance of this protein in normal hemostasis. The biochemical properties of factor IX have been extensively studied. Factor IX is activated from its zymogen to enzyme form by activated factor XI (26) or activated factor VII (27) in a mechanism that involves limited proteolysis. Subsequently activated factor IX, in concert with activated factor VIII, can activate factor X (1, 2, 28). Human factor IX has also been purified to homogeneity (29) and its amino acid sequence determined by analysis of the factor IX gene (30, 31) . For laboratory use, factor IX has been purified by conventional multistep methods, which include barium salt adsorption, ion exchange chromatography, gel filtration, and affini- ty chromatography (15, 16) . Although these methods allow recovery of high quality factor IX, their low overall yield, the extended time required for purification, and potential problems of pyrogen contamination preclude these methods for preparation of factor IX for in vivo replacement therapy. In plasma fractions available for clinical treatment of hemophilia B, factor IX is a minor component. Contamination with activated factor IX and virus particles complicates therapy with thromboembolic disorders and hepatitis (32, 33) . Affinity chromatography has been widely used for the high yield preparation of plasma proteins (14) . However, immunoaffinity chromatography, in which antibodies are covalently linked to solid support, is often complicated by the harsh conditions necessary to disrupt the antibody-antigen complex and the lack of specific elution systems that are optimal for complete purification from crude protein mixtures. The former may be associated with the loss of biological activity, and the latter interferes with the recovery of homogeneous material. These problems are illustrated by Goodall et al. (34) , who observed that a monoclonal antibody directed against factor IX could remove factor IX from plasma; however, the factor IX activity did not survive the conditions necessary for the removal of factor IX from the antibodyagarose matrix. In the current communication, we describe a method of immunoaffinity chromatography using conformation-specific antibodies specific for the metal-stabilized form of factor IX. This method, using a specific binding system of anti-factor IX-Ca(II) antibodies and a specific elution system with EDTA, allows a rapid single step obstacles of post-translational modifications, specifically carboxylation of certain glutamic acid residues to yield ycarboxyglutamic acid, need to be overcome. If sources of factor IX other than plasma do evolve, then the immunoaffinity purification described should also prove useful in the purification of factor IX from the crude protein solution. Immunoaffinity chromatography using antibodies directed against the metal-stabilized conformation of other metalbinding proteins may also have utility in the purification of such proteins. The method of immunoaffinity chromatographic purification for human factor IX that we have described may have potential application in the preparation of factor IX for the treatment of hemophilia B.
